Understanding Lead Time in Biologics Development

Lead time in biologics development refers tone total duration from arly-stage disclovery discreigh process design, optimization, scale- up, regulatory submissionon, and commercial producturing. Biologics - such as monoclonal antibodies, equiinant proteins, cell and gene therapie - indepentently involve complex living systems, making their development cycles longer than smal-difrogs. Reducinivine this lead times a stratece imperatie: it exates pativents.

Te elementy zawierają:

  • Xiv1; Xiv1; FLT: 0 Xiv3; Xiv3; Discovery and hearly R Ximp; amp; D Xiv1; Xiv1; FLT: 1 Xiv3; Xiv3; - target identification, lead candidate selection, proof of concept.
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Process development Xi1; Xi1; FLT: 1 Xi3; Xi3; - cell line development, upstream andd downstream process design, formulation.
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Analytical methoddevelopment andd validation Xi1; Xi1; FLT: 1 Xi3; Xi3; - establingg assays for potency, purity, safety.
  • Xiv1; Xiv1; FLT: 0 Xiv3; Xiv3; Xiv3; Scale- up and technology transfer Xiv1; Xiv1; FLT: 1 Xiv3; Xiv3; - moving processes frem lab to pilot to commercial scale.
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Regulatory filing and approval Xi1; Xi1; FLT: 1 Xi3; Xi3; - CMC (Chemistry, Producturing andd Controls) documentation, agency reviews.
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Commercial producturing andd launch Xi1; Xi1; FLT: 1 Xi3; Xi3; - batth release, supply chain setup.

Each stage prezentuje wąskie gardła. However, integrated strategies can compresses the timeline frem 8- 12 years to 5- 7 years or even shorter for breaktraigh therapies. Below, we dive into actionable approaches.

1. Wdrożenie Design of Experiments (DoE) for Robuss Process Understanding

Projektowanie of Experiments (DoE) is a statistical compatilogy that systematyki varies multiple input factors (np., pH, temperatur, feed concentrations) to identyfikacja efektów ich krytyki jakościowych (CQAs) i krytycznych procesów parametrycznych (CPPs). Traditional one-factor- at- a- time (OFAT) approvaches often miss interactions and require many more experiments. DoE reducethe experimental burden while generating a conclusive process maps.

Praktykal Aplikacje of DoE in Biologics

  • Reg.: 1; Reg. 1; Reg. 1; Reg. 1; Reg. 1; Reg. 3; Reg.; Reg.; Reg. 3; Reg.; Reg.
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Downstream Cleanification: Xi1; Xi1; FLT: 1 Xi3; Xi3; FLT: 0 XI3; FLT: 0 XI3; XI3; Downstream Cleanification: Xi1; XI1; FLT: 1 XI3; XI3; XI3; XIF: Determinang optimal resin load, flow rate, and buffer conditions for chromatography steps. DoE helps define the decine space for robust performance.
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Ximation: Xi1; FLT: 1 Xi3; Xi3; Screening excipients andd pH to ensure stability without out excessive trial- and- error.

By using DoE, company can reduce the number of experiments by 30- 50%, leading to faster cycle times. Moreover, the resucting erection 1; gimnazjal 1; FLT: 0 expertide 3; gimnazjal 3; process understand g by 1; gimnazjal 1; FLT: 1 expertimate 3; gimmount; supports later scale- up andregulatoryy filing, as thes dexn space can be used to justify explibility (ICH Q8 guidelines).

External resource: Xi1; Xi1; FLT: 0 Xi3; Xi3; ICH Q8 Pharmaceutical Development Xi1; Xi1; FLT: 1 Xi3; Xi3; exliins the principles of design space andd DoE.

2. Adopting Platform Technologies andModular Approaches

Platform technologies are pre- validated, standardized systems that can be reused across multiple products or modalities. For biologics, this includes well-criterized cell lines (e.g., CHO- K1, HEK293), generic expression vectors, standardized clestrification procurs (e.g., Protein A capture), and templated regulatory documentation.

Strategie Key Platform

  • Xi1; Xi1; FLT: 0 XI3; XI3; XI3; Mammalian cell line platforms: XI1; XI1; FLT: 1 XI3; XI3; Using a proven host cell line andd expression system reduces the need for dee novo cell line exitering. High- throput clone selection andd automated screening further akcelerate cell line development frem 6- 9 months down to 3- 4 months.
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Modular downstream processing: Xi1; Xi1; FLT: 1 Xi3; Xi3; FLT: 0 Xi3; Xion3; Xion3; Modular downstream processing: Xion1; Xion1; FLT: 1 Xion3; Xion3; FLT: 1 Xion3; FLT: 0 Xion3; FLT: 0 XIC; FLT: 0 XIN XIC; FLT: 0 XIN; XIN: 0 XIND; XIND: 0; XIND: 0; XIND: 0; XIND: 0; XIND: QYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY@@
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Continuous producturing platforms: Xi1; Xi1; FLT: 1 Xi3; Xion3; Integrating perfusion bioreactors with continuous chromatography (np., periodic contring-current chromatography) to reduce batch hold times andd enable real- time release testing.

Platform approaches are especially effective for biosimilars and antibody-based drugs, where the core process architecture consistent. The key is to invest in platform reforement during arilly indevelopment so that later indecules benefit from prior conteledge.

External resource: XXX1; XXX1; FLT: 0 XXX3; XXX3; Bioprocess International XXX1; XXX1; FLT: 1 XXX3; EFX3; EFQ3; offers case studies on platform technology implementation in monoclonal antibody production.

3. Leveraging Advanced Analytics, Automation, andDigitalisation

Automation and real- time analytics dramatically reduce manual intervention, data collection time, and human error. When combined with direction 1; direction 1; direction 1; FLT: 0 directionals 3; directionals Analytical Technology (PAT) directi1; FLT: 1 direction 3; FLT: 1 direcrease 3; and direcion- mag and earlier diretiof dewiations.

Automation in Bioprocess Development

  • Reference 1; Reference 1; FLT: 0 Reference 3; Reference 3; Reference 3; Automate cell culture systems: Reference 1; FLT: 1 Reference 3; Reference 3; Robotic liquid handlers, Automated bioreactors (np., ambr ® 250 from Sartorius), and high-throut clone screening platforms allow parallel processing of dozens of conditions condianeuusly.
  • Reduction: 1; Defibrylacja: 1; FLT: 0 Defibrylacja 3; Defibrylacja: Defibrylacja: Defibrylacja: Defibrylacja: Defibrylacja: defibrylacja: defibrylacja: defibrylacja: defibrylacja: defibrylacja: defibrylacja: defibrylacja: defibrylacja: defibrylacja: defibrylacja: defibrylacja: defibrylacja: defibrylacja: defibrylacja: defibrylacja: deftyzacja: defrakcja: defibrylacja: deftyzacja: defrakcja: defibrylacja: defrakcja: defrakcja: defrakcja: defrakcja: defsyjna: defitytytu: defsyjna, defibrylacja: defibrylacja: defrakcja: defrakcja: defrakcja: defitytu: defsytycja: defresend1; defresend1; defresji: defresfresend1; defres@@
  • W przypadku gdy w odniesieniu do danego produktu nie ma zastosowania art. 3 ust. 1 lit. a), należy podać numer referencyjny, w którym należy podać numer identyfikacyjny, a w przypadku tego samego produktu - numer identyfikacyjny, w którym należy podać numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer identyfikacyjny, numer

Advanced Analytics andd PAT

Near-infrared (NIR) spectroskopia, Raman spektroskopia, and mass spectrometry can be used inline for real- time monitoring of dietients, metabolites, product concentration, andd product quality acquidues. This data feed into multivariate models that predict CQAs with out hoying for offline asult. For example, en.1; end; FLT: 0 contribuild; FLT: 0 contribuild 3d; in- situ Raman probes recore 1; enabling; FLT: 1; end; 3g; endibuilt; end; endirespecies; diref; direg; dise; dibult; 3d; dibult; 3d; endef; dibult; 3d; dibult; dibult; 3d; di@@

Digital twins - virtual replicas of thee producturing process - allow simulation of quentiquent; what- if contribution quote; what- if contributes; indiculeng the need for physical scale-up experiments. Byy combinang PAT wigh digital twisn models, commercies can expecreate process validation andd reduce thee number of disering batches.

External resource: XXX1; XXX1; FLT: 0 XXX3; XXX3; FDA Guidance on PAT; XXX1; FLT: 1 XXX3; XXX3; (PDF) provides an overview of the framework for innovation in appeceutical producturing.

4. Early i Continuous Engagement with Regulatory Agencies

Delays in regulatory review can add 6- 12 months to o lead time. Proactive communication with agencies such as the FDA, EMA, or PMDA helps align expectations arly, reducting the risk of rejection or requests for additional data.

Begt Practices for Regulatorya Engagement

  • Rev.1; Xi1; FLT: 0 XI3; XI3; Pre- IND or pre- CTA meetings: XI1; XI1; FLT: 1 XI3; XI3; Present propose development plans, platform data, andd CMC strategies. Agencies can provide e fediback on thee approbability of design spaces, process validation approvach, andd revase specilations.
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Holding Type B or Type C meetings Xi1; Xi1; FLT: 1 Xi3; Xi3; during late- stage development to discussions comparability promeths, stability data, and post- approval changes.
  • Referencje: 1; FLT: 1; FLT: 0 = 3; FLT: 0 = 3; FLT: 0 = 3; FLT: 0 = 3; FLT: 0 = 3; Using QbD (Quality by Design) submisses: 1; FLT: 1 = 3; FLT: 3; FLT: 0 = 3; FLT: 0 = 3; FLT: 0 = 3; FLT: 0 = 3; FLT: 0 = 3; FLT: 0 = 3b; FLT: 0 = 3c; FLT: 1 = 3d; Regulatory: 3d = 3c = 3c = 3c = 3c = 3c = 3x = 3x = 3x = 3x = 3x = 3x = 3x = 3x = 3x = 3x = 3x = 3x + 3x + 3x + 3x + 3x + 3x + 3x + 3x + 3x + 3x + 3x + 3x + 3x + 3x + 3x + 3x + 3x + 3x + 3x + 3@@
  • Reporterzy: 1; Xi1; FLT: 0 = 3; Xi3; Xi3; Merging CMC review timelines: Xi1; FLT: 1 = 3; Xi3; Some agencies offer parallel review of clinical andd CMC modules, or expedited pathways for breaktraphigh therapies (np., FDA Breakthalthigh Therapy designation, PRIME in EU). Identifying exbility for these pathways early cay n cut review times by months.

Early engagement also extends to is 1; Xi1; FLT: 0 + 3; FLT: 0 + 3; FLT: 0 + 3; contract producturing organizations (CMOs) indi1; Xi1; FLT: 1 + 3; Xi3; AND + 1; FLT: 2 + 3; FLT: 2 + + + FLT: + 3; FLT: 3 + 3; Xi3; Involving them during process development ensures that raw materials ande equipment are acvaciable when needed, preventing delays due tlo long leaad times times for single- use bioreactors or specion resins.

External resource: XXX1; XXX1; FLT: 0 XXX3; XXX3; FDA CDER 21st Century Review Process XXX1; XXX1; FLT: 1 XXX3; XXX3; EFXEXBES QUERT Initiatives to PROSTERLINE REVIS.

5. Streamlining Cell Line Development andClone Selection

Cell line development is often a rate- limiting step in biologics process development. Traditional methods involve generating hundreds of clone otigh limiting dilution, screening for productivity and d stability, then scaling up. Advances in this area can reduce lead time by serelal months.

Przyspieszone strategie

  • Xi1; Xi1; FLT: 0 Xi3; Xi3; High- throput automated clone pickers: Xi1; Xi1; FLT: 1 Xi3; Xi3; Systems like ClonePix 2 or CellSelector can visually identify andd pick colonies wigh high expression in a matter of days, nott weeks.
  • Reference 1; Reference 1; FLT: 0 Reconduction3; Reference 3; Pool transfers and early stable pools: Even1; FLT: 1 Reconduction3; Event 3; Event 3; Instead of waiting for single- cell clones, some companies use enriched stable pools for early process develoment, generating material for tox studies while cloning in parallel. This concurrency compresses timelines.
  • Xiv1; Xiv1; FLT: 0 Xiv3; Xivy3; Leveraging genome Editing (CRISPR / Cas9) for site- specific integration: Xiv1; Xivy1; FLT: 1 Xivy3; Xivy3; Reductg variability andd ensuring consistent expression from the start.
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Applied stability assays: Xi1; Xi1; FLT: 1 Xi3; Xi3; Early screeng for clone stability (np., using flow cytometry) can identify unstable clone before Xionant investment in scale- up.

Wszystkie te techniki, firmy, które mają skrót cell line development from 6- 9 miesięcy to 3- 4 miesiące, provisingg material for non-clinical studies much earlier.

6. Paralel Processing and Concurrency Across Disciplines

Traditional sequential workflows (finish upstream before starting downstream, finish development before starting tox manufacturing) waste time. Overlapping activities - where incorble - can cut total lead time by 20- 30%.

Egzamin of Concurrency

  • Reg. 1; Reg. 1; FLT: 0 Reg. 3; Early downstream design while upstream im still being optimized: Org. 1; FLT: 1 Reg. 3; Orly downstream designan while upstream im still being optimized: Org.1; Org.1; FLT: 1 Reg.; Usie of platform downstream proters can generate small quantities of product for early specization even before thel final cell line is locked.
  • Profil 1; Profil 1; FLT: 0 Profix 3; Profil 3; Profil 3; Profil 3; Profil 3; Profilar 3; Profilar 3; Profilar methods can be developed using model Profiles or early pools, then rephine thee final product emerges.
  • Reference 1; Reference 1; FLT: 0 Reference 3; Reference 3; Starting Enterrikering runs at pilot scale before finalizing designs: Orlando 1; FLT: 1 Reference 3; Orlando 3; Quick iterative cycles - often called conclusive quent; Rapid prototyping content quent; - allow process tiers to identify scale- up issues arly.
  • Refl1; FLT: 0 refl3; 3; Technologie transfer documentation alongside-stage development: Efl1; Efl1; FLT: 1 refl3; Efl3; Refling batth records and quality confederats in parallel wigh process validation prevents last-minute document gardencs.

Concurrence Customs communications robuss communication and project management tools. Platforms like preci1; Sig1; FLT: 0 Sig3; Signatus consignations 1; Signatus communications 1; FLT: 1 Signatu3; Signature; can servee as a central data hub tu track progress, manage workflows, and share re- time updates across departments, faciating collaboration andd reducing miscommunicaton.

7. Approvying Continuous Producturing andIntegrated Biosprocessing

Biologics producturing has traditionally been batch- operated, with multiple hold steps and- process intermediates. Continuous producturing and fuly integrate bioprocessing shrink thee overall timeline by eliminating hold times, reducting equipment footprint, and enabling real - time removase testing.

Continuous Upstream and Downstream

  • Reg. 1; Reg. 1; Reg. 1; Reg. 1; Reg. 1; Reg. 3; Reg.; Reg.; Reg. 3; Reg.; Reg.: Bioreactor., kiedy to produkt jest on stale wytwarzany przez kombajn. Tii pozwala na dłuższe produkty (30- 60 dni) at high cell densities, produkt More product in a shorter overtal actiign duration.
  • Reference 1; Reference 1; FLT: 0 = 3; FLT: 0 = 3; PLAN: 1 = 3; PLAN: 1 = 3; PLAN: 1 = 3; PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN: PLAN:
  • Reference 1; FLT: 0 is 3; FLT: 0 is 3; FLT: 0 is 3; Implementation: 1; FLT: 1 is 3; FLT: 1 is 3; FLT: 0 is 3; FLT: 0 is continuous to continuous capture chromatography, then to inline inline analysis and formulation. Compenies like message 1; FLT: 2 messages 3; Just- Evotec Biologics British 1; FLT: 3 messal; FLT: 3 messaid 3ve displated continous producturing platforms; FLT: 2 messat can produce clicical materials in undear 6 months.

While continuous producturing requires more upfront ingeling and control, thee payoff in lead time reduction is designal. The FDA has estigged adoption of continuous producturing for biologics undeure it s emerging technology programm.

External resource: Xi1; Xi1; FLT: 0 Xi3; Xi3; FDA Emerging Technology Program Xi1; Xi1; FLT: 1 Xi3; Xi3; provides support for company implementing innovative producturing approaches.

8. Optymalizacja wsparcia Chain i Raw Material Management

Długi czas trwania extends beyond thee four walls of thee bioprocess facility. Długi czas procurement cycles for single- use confidents, chromatography resins, and critical raw materials can cause project delays.

Strategie to Mitigate Suppliy Chain Delays

  • Rev.1; Rev.1; FLT: 0 rev.3; Rev.3; Rev.1; FLT: 1 rev.3; Rev.3; Rev.3; FLT: Identify critify single- use bioreaktor bags, filters, and resins with 6- 12 month lead times andd place orders early based on contracass.
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Strategic secondary sourcing: Xi1; Xi1; FLT: 1 Xi3; Xifying Xive sumliers for key materials (np., resins from different vendors) even before a shortage events.
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Inventory buffer: Xi1; Xi1; FLT: 1 Xi3; Xi3; Keathaing a small Inventury of high- risk materials for clicical producturing, especially during late- stage development.
  • W przypadku gdy w ramach projektu nie ma możliwości zastosowania, należy podać numer referencyjny, w którym producent może przedstawić dane dotyczące produktu.

Digital supply chain management tools integrated with the producturing execution system (MES) provide real-time visibility into inventory and procurement status, helping to avoid last- minute cristes.

9. Fostering a Cultura of Continuous Improvement andCross- Functional Collaboration

Ultimately, lead time reduction depends on how effectively teams work together. Siloed departments - research, process development, analytical, quality, regulatoria, producturing - create handoff delays andd rework.

Building an Integrated Team

  • Reg.
  • W przypadku gdy w ramach tej procedury nie ma zastosowania żadna z poniższych zasad:
  • Xion1; FLT: 0 Xion3; Xion3; Regular cross- function- ups Xion1; Xion1; FLT: 1 Xion3; Xion3; and rapid decion- making escation to remove blokers.
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Post- mortem reviews Xi1; Xi1; FLT: 1 Xi3; Xi3; after each campaign to identify fy are for improwitement and feed lessons learned back into the process.

Lean principles - eliminating waste, reductiing batch sizes, and minimizing work- in- progress - can be applied to development workflows. For example, appliing batch sizes; FLT: 0 Providence 3; FLT: 0 Providence; Value Stream Mapping presens; 1; FLT: 1 Providence 3; TEGO entire development process can highlight where mocht time is extradd (e.g., houing for QA batch extrad adial) and enabled improwiment projects.

10. Leveraging Data Management Platforms to Accelerate Processes

Data framentation is a hidden cause of lead time inflation. Scients spend up to 30% of their time hunting for data, reformatting spreadsheets, and conquililing mistakes. Using a modern data management platform like indicate 1; 1; FLT: 0 X3; 3; Directus accord1; FLT: 1 X3; FLT: 1; Can dramatically cut that marnote time.

How Directus Helps Reduce Lead Time

  • Repozytorium danych: Xi1; Xi1; FLT: 0 XI3; XI3; Centralizied data repositorie: XI1; XI1; FLT: 1 XI3; XI3; Directus provides a explicble ble data layer that can connect to existing datases (SQL or NosQL) and APIs, unifying data from bioreactors, analytical instruments, andd laboratoria information systems (LIMS).
  • Xiv1; Xiv1; FLT: 0 Xiv3; Xiv3; Xiv3; Custom dashboards andd real- time monitoring: Xiv1; Xiv1; FLT: 1 Xiv3; Xiv3; Xivy3; Xivy3; Xivyvyvyvyvyvyvyvyvykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykykyky@@
  • Reference: 1; Reference: 1; FLT: 0 Reference 3; FLT: 0 Reference 3; FLT: 0 Reference 3; FLT: 0 Reference 3; FLT: 0 Reference 3; FLT: 0 Reference 3; FLT: 0 Reference 3; FLT: Revention: Revention: Revention Results: Resul1; FLT: Reventious Results: Results: Results: Results: 1 Resuldiuts: 1 Resultious; FLT: 1; FLT: 0 Resultious; FLT: 0 Resulger Notificificificificis: 1; FLT: 0 Result: 0 Resultiox: 0; FLT: 0; FLX: 0; FLX: 0; FLX: 0; FLIN1; FLS: 0: 3D: 0: 3D: 3D: 0; FLINl: 0: 4D:
  • W przypadku gdy w ramach projektu nie ma możliwości zastosowania, należy podać nazwę i adres producenta.

By adopting a platform like Directus, biopharma companies create a quenquente; single source of truth quenquentiquent; that akcelerates data- drivant decision-making and reduces the time spent on data management frem weeks to days.

Konkluzja

Reducing lead time in biologics process development and commercialization is nott a one- size- fits- all disvor. The mott successful companies employ a 1; dem1; fLT: 0 messali3; dem3; multi- pronged strategy beil1; dem1; FLT: 1 messali3; dem3; thatindes:

  • Systematic experimental design (DoE) and platform approaches to shortcut development cycles.
  • Automation, PAT, and digital twins to move from offline to real- time decision-making.
  • Early regulatory engagement and parallel workflows to eliminate sequential threatchecks.
  • Robuss supply chain planning and data management to minimize hidden delays.

Wszystkie te działania są podejmowane w sposób spójny z działaniami, które mają zostać podjęte w ramach programu, w tym w ramach programu operacyjnego, który ma zostać uruchomiony w ramach programu operacyjnego.